Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies

Implications of the Hippo Pathway Dysregulation in Uterine Leiomyosarcoma

ANASTASIOS KYRIAZOGLOU, DIONYSIOS J. PAPACHRISTOU, MYRTO MOUTAFI, ALEXANDRA PAPAKOSTA, ALKISTIS PAPATHEODORIDI, MARIA KAPARELOU, ANNA MARIA KORAKITI, MICHALIS LIONTOS, MELETIOS ATHANASIOS DIMOPOULOS and FLORA ZAGOURI
Anticancer Research August 2024, 44 (8) 3331-3336; DOI: https://doi.org/10.21873/anticanres.17152
ANASTASIOS KYRIAZOGLOU
1Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: tassoskyr{at}gmail.com
DIONYSIOS J. PAPACHRISTOU
2Department of Anatomy-Histology-Embryology, University of Patras, School of Medicine, Patras, Greece;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MYRTO MOUTAFI
1Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ALEXANDRA PAPAKOSTA
3Department of Genetics, Agios Savvas Anticancer Hospital, Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ALKISTIS PAPATHEODORIDI
1Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MARIA KAPARELOU
1Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ANNA MARIA KORAKITI
1Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MICHALIS LIONTOS
1Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MELETIOS ATHANASIOS DIMOPOULOS
1Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
FLORA ZAGOURI
1Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background/Aim: Uterine leiomyosarcomas (uLMS) are the most common mesenchymal tumors of the female genital tract. uLMS genetics encompass complex karyotypes with no specific molecular alterations. The Hippo pathway has been implicated in the pathogenesis of epithelioid hemangio-endotheliomas and endometrial sarcomas. Hippo pathway effectors are YAP1 and TAZ co-transcriptional factors. Patients and Methods: We studied Hippo pathway in a series of 32 uLMS patients and its association with clinicopathological parameters. Materials and Methods: Immunohistochemical analysis of YAP1 and TAZ proteins accompanied with fluorescent in situ hybridization study of YAP1 gene was performed in patient samples. Age, sex, tumor size, stage at the time of diagnosis and treatment have been analyzed. Overall survival (OS) was calculated from the time of diagnosis until death, loss of follow up or data cut-off. Results: Hippo signaling was found to be dysregulated in 20 (62.5%) patients with uLMS. Regarding OS we detected a trend of Hippo deregulation, designating it as a positive prognostic factor. Conclusion: The Hippo pathway is implicated in uLMS oncogenesis, since nuclear expression of YAP1 was detected in 17 (53.1%) of the 32 patients with immunohistochemistry and YAP1 amplification was found in 8 (25%) patients.

Key Words:
  • Uterine leiomyosarcoma
  • Hippo pathway
  • YAP1
  • prognosis
  • Received April 9, 2024.
  • Revision received May 23, 2024.
  • Accepted May 27, 2024.
  • Copyright © 2024 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
View Full Text

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.

patientACCESS

patientACCESS - Patients desiring access to articles
PreviousNext
Back to top

In this issue

Anticancer Research: 44 (8)
Anticancer Research
Vol. 44, Issue 8
August 2024
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Implications of the Hippo Pathway Dysregulation in Uterine Leiomyosarcoma
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
16 + 1 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Implications of the Hippo Pathway Dysregulation in Uterine Leiomyosarcoma
ANASTASIOS KYRIAZOGLOU, DIONYSIOS J. PAPACHRISTOU, MYRTO MOUTAFI, ALEXANDRA PAPAKOSTA, ALKISTIS PAPATHEODORIDI, MARIA KAPARELOU, ANNA MARIA KORAKITI, MICHALIS LIONTOS, MELETIOS ATHANASIOS DIMOPOULOS, FLORA ZAGOURI
Anticancer Research Aug 2024, 44 (8) 3331-3336; DOI: 10.21873/anticanres.17152

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Implications of the Hippo Pathway Dysregulation in Uterine Leiomyosarcoma
ANASTASIOS KYRIAZOGLOU, DIONYSIOS J. PAPACHRISTOU, MYRTO MOUTAFI, ALEXANDRA PAPAKOSTA, ALKISTIS PAPATHEODORIDI, MARIA KAPARELOU, ANNA MARIA KORAKITI, MICHALIS LIONTOS, MELETIOS ATHANASIOS DIMOPOULOS, FLORA ZAGOURI
Anticancer Research Aug 2024, 44 (8) 3331-3336; DOI: 10.21873/anticanres.17152
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Conclusion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Insights From Matrix Metalloproteinase-2 Genotypes to Decipher the Genetic Architecture of Bladder Cancer Risk
  • Chemosensitizing Effects of Resveratrol Derivatives on p53-dependent Apoptosis Triggered by Cisplatin in Human Lung Cancer Cells
  • Advanced Reliability of Radiomic Features in Ex Vivo HypersightTM-CBCT Imaging by iCBCT-Acuros Reconstruction
Show more Experimental Studies

Keywords

  • Uterine leiomyosarcoma
  • Hippo pathway
  • YAP1
  • prognosis
Anticancer Research

© 2026 Anticancer Research

Powered by HighWire